Enovis Corporation (ENOV) Cash Flow Statement

The persistent gap between net income and operating cash flow is driven by large non-cash charges, primarily D&A averaging $73M per quarter and impairment charges in 2024Q4 and 2025Q3. This suggests that the company's underlying cash generation is far stronger than GAAP earnings imply, but the quality of earnings is heavily dependent on non-cash adjustments. Investors should monitor whether the gap narrows as acquisition-related amortization and impairments subside.

The trajectory shows a clear improvement from the trough in early 2024, but the path has been volatile, with negative FCF in 2025Q1 and 2026Q1. The most recent quarter's FCF margin of 5.3% remains well below peers like Hologic (24.2%) and LeMaitre (28.1%), indicating that the company is still in the early stages of cash flow normalization. The sustainability of this recovery depends on continued revenue growth and disciplined capex management.

The capital intensity is moderate for a medical device manufacturer, but the consistent capex levels suggest ongoing investment in manufacturing capacity and product development, likely tied to the LimaCorporate integration and expansion of the Recon segment. While some of this capex may be maintenance-related, the company's focus on high-growth surgical platforms implies a growth-oriented allocation. Investors should assess whether these investments translate into higher revenue and margins over time.

The large swings in working capital, particularly the negative changes in early 2024 and 2025, suggest that the company has faced challenges in managing receivables and inventory, possibly due to the integration of acquired businesses. The positive changes in late 2024 and 2025 indicate improved efficiency, but the recent negative change in 2026Q2 warrants monitoring. If working capital continues to be a drag, it could pressure cash flow despite operational improvements.

The company's capital deployment strategy is clearly oriented toward growth through M&A, with the LimaCorporate acquisition being the most significant. The absence of shareholder returns suggests that management is prioritizing reinvestment and debt reduction, but the heavy acquisition spending has contributed to the negative net margins and elevated leverage. Investors should monitor whether future M&A is funded through cash flow or additional debt, as the latter could strain the balance sheet.

This massive divergence underscores the impact of non-cash charges, particularly impairments and amortization, which have obscured the company's underlying cash-generative ability. The positive operating cash flow despite persistent losses suggests that the core business is viable, but the cumulative losses raise questions about the long-term profitability of the acquired assets. The gap is likely to narrow as acquisition-related charges fade, but investors should remain cautious until net income turns positive.